Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 10, 2011, Pages 2386-2392

  Walraven, Carla J ^a   North, Michael S ^a   Marr Lyon, Lisa ^a   Deming, Paulina ^a   Sakoulas, George ^b   Mercier, Renée Claude ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b SHARP MEMORIAL HOSPITAL   (United States)

Author keywords

Endocarditis; Mrsa; Pneumonia

Indexed keywords

CLINDAMYCIN; DOXYCYCLINE; PANTON VALENTINE LEUKOCIDIN; SULFAMETHOXAZOLE; TRIMETHOPRIM; VANCOMYCIN;

ADD ON THERAPY; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL STRAIN; BLOOD CULTURE; DIARRHEA; DISEASE COURSE; DRUG FEVER; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOCARDITIS; FEMALE; GENE CONTROL; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; PNEUMONIA; PROTEIN EXPRESSION; RASH; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL TOXINS; ENDOCARDITIS, BACTERIAL; EXOTOXINS; FEMALE; HOSPITAL MORTALITY; HUMANS; LEUKOCIDINS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT FAILURE; VANCOMYCIN;

EID: 80052903803     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr301     Document Type: Article

References (35)

1. Levine DP. Vancomycin: a history. Clin Infect Dis 2006; 42: S5-12.
2. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008; 46: S360-7.
3. Lodise TP, Graves J, Evans A et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315-20.
4. Dombrowski JC, Winston LG. Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections. J Infect Dis 2008; 57: 110-5.
5. Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200.
6. Kettle JK, Grace JW, Schaefer RS et al. Methicillin-resistant Staphylococcus aureus with a minimum inhibitory concentration of mcg/mL. Hosp Pharm 2010; 45: 375-80.
7. Peleg AY, Monga D, Pillai S et al. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J Infect Dis 2009; 199: 532-6.
8. Price J, Atkinson S, Llewelyn M et al. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin Infect Dis 2009; 48: 997-8.
9. Lalueza A, Chaves F, San Juan R et al. Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia? J Infect Dis 2010; 201: 311-2.
10. Musta AC, Riederer K, Shemes S et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteraemia: trends over 11 years. J Clin Microbiol 2009; 47: 1640-4.
11. Fong RK, Low J, Koh TH et al. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur J Clin Microbiol Infect Dis 2009; 28: 983-7.
12. Maor Y, Hagin M, Belausov N et al. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199: 619-24.
13. Fowler VG, Sakoulas G, McIntyre LM et al. Persistent bacteraemia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in-vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 2004; 190: 1140-9.
14. Sakoulas G, Moellering RC, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 2006; 42: S40-50.
15. Sakoulas G, Eliopoulos GM, Moellering RC Jr et al. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 2003; 187: 929-38.
16. Löffler B, Hussain M, Grundmeier M et al. Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog 2010; 6: e1000715.
17. Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest 2007; 87: 3-9.
18. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
19. Moise-Broder PA, Forrest A, Birmingham MC et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925-42.
20. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42: S35-9.
21. Lodise TP, Patel N, Lomaestro BM et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49: 507-14.
22. Hermsen ED, Hanson M, Sankaranarayanan J et al. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010; 9: 9-14.
23. Hidayat LK, Hsu DI, Quist R et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med 2006; 166: 2138-44.
24. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55.
25. Rolston KV, Segreti J, Lamp KC et al. Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med 2007; 120: S4-5.
26. Etest for MIC determination [package insert]. Solna, Sweden: BioMerieux Inc., 2009.
27. Sakoulas G, Eliopoulos GM, Moellering RC Jr et al. Accessory gene regulator locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46: 1492-502.
28. Johnsson D, Molling P, Stralin K et al. Detection of Panton-Valentine leukocidin gene in Staphylococcus aureus by LightCycler PCR: clinical and epidemiological aspects. Clin Microbiol Infect 2004; 10: 884-9.
29. Deurenberg RH, Vink C, Driessen C et al. Rapid identification of Panton-Valentine leukocidin from clinical isolates of Staphylococcus aureus strains by real-time PCR. EMFS Microbiol Lett 2004; 240: 225-8.
30. McDougal LK, Steward CD, Killgore GE et al. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003; 41: 5113-20.
31. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more receiver operating characteristic curves: a non-parametric approach. Biometrics 1988; 44: 837-45.
32. Harigaya Y, Bulitta JB, Forrest A et al. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia. Antimicrob Agents Chemother 2009; 53: 3894-901.
33. Tsuji BT, Harigaya Y, Lesse AJ et al. Loss of vancomycin bactericidal activity against accessory gene regulator (agr) dysfunctional Staphylococcus aureus under conditions of high bacterial density. Diagn Microbiol Infect Dis 2009; 64: 220-4.
34. Lalani T, Federspiel JF, Boucher HW et al. Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients. J Clin Microbiol 2008; 46: 2890-6.
35. Price J, Baker G, Heath I et al. Clinical and microbiological determinants of outcome in Staphylococcus aureus bacteremia. Int J Microbiol 2010; 2010: 654858.